The beat-and-raise quarter with strong HVP and biologics growth confirms accelerating demand for West's high-value injectable components. Traders should watch for continued margin expansion and any updates on the SmartDose sale to AbbVie. The raised guidance provides a clear upward catalyst for the stock in the near term.
Price Chart
Executive Summary
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating consensus estimates of $840M and $2.08. The company raised full-year 2026 adjusted-diluted EPS guidance to $8.85-$9.05 (from $8.40-$8.75) and net sales guidance to $3.345B-$3.380B, driven by strong HVP Components (+19.4%) and Biologics (+30.3%) growth. The beat and raised guidance signal accelerating demand for injectable solutions, particularly in GLP-1 and biologics, making this a clear positive catalyst for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 net sales of $872.3M beat $840M consensus (+3.8% surprise)
- Diluted EPS of $2.15 beat $2.08 consensus (+3.4% surprise)
- Adjusted-diluted EPS of $2.37 increased 28.8% YoY
- Full-year 2026 adjusted-diluted EPS guidance raised to $8.85-$9.05 from $8.40-$8.75
- Full-year 2026 net sales guidance raised to $3.345B-$3.380B from $3.295B-$3.350B
- HVP Components net sales grew 19.4% to $424.1M, 49% of total sales
- Biologics market group net sales grew 30.3% to $374.8M
- Operating cash flow was $213.9M; free cash flow was $128.0M
- Company repurchased 1.8M shares for $454.3M in H1 2026
Financial Impact
Beat consensus by $32.3M on revenue and $0.07 on EPS; raised full-year EPS guidance by $0.45 at midpoint
Risk Factors
- SmartDose 3.5mL sale to AbbVie creates a $55M revenue headwind in H2 2026
- Foreign exchange headwinds of ~1% on full-year guidance
- Cost-method investment impairment of $3.5M in Q2
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302832704 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 23, 2026 10w ago | 8-K | $355.48 $353.77 | ▼ −0.48% | ▼ −3.79% | $364.89 (+2.65%) |
Jul 23, 2026 10w ago | Press Release | $355.48 $353.77 | ▼ −0.48% | ▼ −3.79% | $364.89 (+2.65%) |
Jul 7, 2026 12w ago | Press Release | $356.08 $347.94 | ▼ −2.29% | ▼ −3.62% | $364.89 (+2.47%) |
May 11, 2026 20w ago | 8-K | $311.82 $330.92 | ▼ −6.12% | ▼ −7.85% | $364.89 (−17.02%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access